Iq Ai Stock Price, News & Analysis
IQAIF
OTC
Company Description
IQ AI LTD (IQAIF) is a company that owns Imaging Biometrics, LLC, a subsidiary focusing on delivering quantitative imaging platforms and therapeutics for efficient patient diagnosis and treatment. Recently, Imaging Biometrics received Orphan Drug Designation from the US FDA for gallium maltolate (GaM) in the treatment of pediatric glioblastoma multiforme (GBM), showcasing significant survival benefits in pre-clinical studies. With a strong focus on innovation and improving patient outcomes, IQ AI LTD continues to make strides in the healthcare industry.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$4.4M
Market Cap
246.7M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Iq Ai.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the market cap of Iq Ai (IQAIF)?
The market cap of Iq Ai (IQAIF) is approximately 4.4M.
What does IQ AI LTD (IQAIF) focus on?
IQ AI LTD focuses on delivering quantitative imaging platforms and therapeutics through its subsidiary Imaging Biometrics, LLC.
What recent achievement did Imaging Biometrics, a subsidiary of IQ AI LTD, obtain?
Imaging Biometrics recently received Orphan Drug Designation from the US FDA for gallium maltolate in the treatment of pediatric glioblastoma multiforme.
What is the significance of Orphan Drug Designation for GaM in pediatric GBM treatment?
Orphan Drug Designation confirms the potential and benefits of GaM in treating a condition with no effective treatments currently available.
How did GaM perform in pre-clinical studies for pediatric GBM?
GaM demonstrated a significant survival benefit in pre-clinical studies, with median overall survival more than 2x longer in treated groups.
Who leads the innovative efforts at IQ AI LTD?
Trevor Brown, CEO of IQ AI LTD, oversees the company's innovative initiatives and strategic direction.
What is the focus of Imaging Biometrics, LLC, a subsidiary of IQ AI LTD?
Imaging Biometrics focuses on delivering quantitative imaging platforms and therapeutics to enhance patient diagnosis and treatment.
Where can more information about Imaging Biometrics be found?
For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.
What recent study results were presented at the 2023 Society of Neuro Oncology (SNO) Pediatric Conference?
Results of a pre-clinical study showing significant survival benefits of GaM in pediatric GBM were presented at the conference.
Why is GaM considered an attractive potential treatment option for patients?
The easy administration by capsule and promising results make GaM a viable treatment option for both pediatric and adult patients.
Who is Dr. Kathleen Schmainda and Dr. Mona Al-Gizawiy, and what role did they play in the study?
Dr. Kathleen Schmainda and Dr. Mona Al-Gizawiy from the Medical College of Wisconsin (MCW) led the pre-clinical study demonstrating the benefits of GaM in pediatric GBM.
How does IQ AI LTD contribute to the healthcare industry?
Through its subsidiary Imaging Biometrics, IQ AI LTD contributes to the healthcare industry by providing innovative imaging platforms and therapeutics for enhanced patient care.
What is the impact of the recent Orphan Drug Designation from the US FDA for GaM?
The Orphan Drug Designation signifies the potential of GaM in addressing the unmet medical needs of pediatric glioblastoma multiforme patients.
How does IQ AI LTD differentiate itself in the healthcare sector?
IQ AI LTD stands out in the healthcare sector by focusing on innovative solutions and transformative technologies for efficient patient diagnosis and treatment.